The Efficacy of Si-Ni-Tang (a Chinese Herbal Formula) for Severe Sepsis
NCT02777606 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2023-09-13
Summary
The purpose of this study is to evaluate the efficacy of Si-Ni-Tang (a Chinese Herbal Formula documented in Shang Han Lun) in treating severe sepsis.
Conditions
- Severe Sepsis
Interventions
- DRUG
-
Si-Ni-Tang
Treatment adheres to the International guidelines for management of severe sepsis and septic shock( 2012) and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015 for both the treatment group and the control group. In addition, 150ml of Si-Ni-Tang will be given by p.o. or by a nasogastric tube once a day for 3 days in the treatment group.
Sponsors & Collaborators
-
Guangdong Provincial Hospital of Traditional Chinese Medicine
lead OTHER
Principal Investigators
-
Fang Lai, Master · Guangdong Provincial Hospital of Traditional Chinese Medicine
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-06-30
- Primary Completion
- 2018-12-31
- Completion
- 2019-04-30
Countries
- China
Study Locations
More Related Trials
-
Shenfu Injection Modulates Carotid Elasticity in Septic Shock
NCT06915506 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Pharmacokinetics of XueBiJing in Patients With Sepsis
NCT03475732 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Thymosin alpha1 for Severe Sepsis
NCT00711620 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis
NCT05634057 ·Status: RECRUITING ·Phase: NA
-
Clinical Research on Shenfu Injection in Septic Patients
NCT06157320 ·Status: RECRUITING ·Phase: NA
-
Immune Function Monitoring and Immunotherapy in Sepsis
NCT04903405 ·Status: UNKNOWN
-
Serial Body Composition Change for Risk Prediction and Nutritional Guide in Treating Patients With Sepsis
NCT04989569 ·Status: COMPLETED ·Phase: NA
-
The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Sepsis
NCT03340649 ·Status: UNKNOWN
-
Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients
NCT05911711 ·Status: UNKNOWN
-
Clinical Characteristics and Risk Factors for In-Hospital Mortality in Surgical Patients With Abdominal Sepsis
NCT06756750 ·Status: COMPLETED
-
The Efficacy of YiQiFuMai Injection as an Adjunctive Treatment for Sepsis
NCT05265130 ·Status: UNKNOWN ·Phase: PHASE4
-
Evaluation of Droplet Digital PCR Rapid Detection Method and Precise Diagnosis and Treatment for Suspected Sepsis
NCT05190861 ·Status: COMPLETED ·Phase: NA
-
The Efficacy and Safety of Ta1 for Sepsis
NCT02867267 ·Status: COMPLETED ·Phase: PHASE3
-
Study on the Construction and Application of Early Warning Model of Sepsis in Critically Ill Patients
NCT06904001 ·Status: ENROLLING_BY_INVITATION
-
Objective Sepsis Identification Tool to Study Sepsis Epidemiology
NCT04114214 ·Status: COMPLETED
-
Regulatory Network and Diagnostic Value of Key Autophagy-related Genes in Sepsis
NCT05524376 ·Status: UNKNOWN
-
Neutrophil Elastase Inhibitor in Treatment of ARDS Patients With Mechanical Ventilation Caused by Sepsis
NCT05672472 ·Status: UNKNOWN ·Phase: NA
-
Continuos Terlipressin Infusion in Septic Shock
NCT01697410 ·Status: UNKNOWN ·Phase: NA
-
The Prognostic Value of Lactate is Different Among Septic Patients
NCT04155060 ·Status: COMPLETED
-
Epidemiology of Sepsis in China
NCT02448472 ·Status: COMPLETED
-
Prolonged Intravenous Infusion of β-lactam Antibiotics in Early Septic Patients
NCT05024565 ·Status: UNKNOWN ·Phase: NA
-
Effect of Immunophenotype on Prognosis of Sepsis
NCT05602584 ·Status: UNKNOWN
-
Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepsis
NCT04973670 ·Status: UNKNOWN ·Phase: PHASE3
-
The Efficacy of Xuebijing Injection on Sepsis
NCT03238742 ·Status: COMPLETED ·Phase: PHASE4
-
Urine Interleukin-37 as a Biomarker of Mortality Risk in Patients With Sepsis
NCT05640037 ·Status: COMPLETED